

Index

- Aalbersberg, Bill, 263
- Abbott, 314
- ABCD model of transfer of IP rights, 85
- downstream transfers, 266
 - open access and, 181, 182
 - procurement practices and, 153–154
- Academic freedom, 298
- Acambis, 332
- Access and benefit sharing agreements, 304 (*See* Biodiversity)
- “Accessible domain” (*See* Public Domain)
- broadly accessible information, 49
 - concerns, 51
 - enlargement of, 57
 - fully accessible information with no IP rights, 48–49
 - infringement and, 91
 - limited purposes, information accessible for, 49–50
 - mapping of, 48
 - non-accessible information, 50
 - relative strength of IP rights, significance of, 50–51
 - spectrum of information contained in, 50
 - tree metaphor and, 64–65
- Access to innovation
- access not readily available, when, 231–238
 - access readily available, when, 229–231
 - alternatives, seeking, 232–234
 - balancing with exclusion (*See* Balancing access and exclusion)
 - bargaining chips, 234
 - blocking rights, 237
 - challenging IP rights, 237–238
 - “chilling effect” of IP rights, 228–229
 - compulsory licenses, 236
 - decision trees, use of, 229
 - “designing around” patents, 234
 - duration of IP rights, limits on, 232
 - fair use (*See* Fair use)
 - first sale doctrine and, 229–231
 - freedom to operate analysis, 228, 235
 - geographical scope of IP rights, limits on, 232
 - government use, 236–237
 - innovation cycle and (*See* Innovation cycle)
 - legal defects in IP rights, seeking, 234–235
 - license, by, 231
 - litigation and, 237
 - music, 231
 - negotiation and, 237
 - open access (*See* Open access)
 - overview, 238
 - pharmaceuticals, 231–232
 - plants, 231
 - purchase, by, 231
 - respecting IP rights, 228
 - screening of innovations, 227–228
 - software, 231
 - third-party IP rights, 237
 - weakness in scope of IP rights, seeking, 232
- Acetaminophen, 124
- Acquisition of IP rights (*See* Copyrights, Patents, Trademarks, and Trade Secrets)
- ABCD model and, 266
 - balancing of rights, 266
 - creation, via, 265–266
 - downstream transfers, 266
 - overview, 265
 - partnering relationships, 266
 - transfer agreement, via, 266
- Adobe Acrobat Reader, 172, 231
- Aeschylus, 28
- African Intellectual Property Organization (OAPI), 33
- African Regional Intellectual Property Organization (ARIPO), 33, 320
- Africa Rice Center (WARDA), 107, 108
- Agence France Presse, 136
- Agreement on Trade-Related Aspects of Intellectual Property Rights. *See* TRIPS Agreement

Index

391

- Agriculture and developing countries, 55, 107–108
- AIDS medicines
Brazil, in, 128
conversion to different type of IP, 79
public domain and, 47
unnamed co-inventor and AZT, 178
- Alcatel-Lucent, 315
- “Aleppo Citadel” strategy, 170
- Alexander the Great, 13
- Allied Domecq, 317
- Alternate dispute resolution, comparative law re, 313
- Amazon.com, 140, 306
- American Academy for the Advancement of Science, 298
- American Arbitration Association, 313
- American Type Culture Collection, 292
- Andean Community (ANCOM), 320
- Andean Pact, 33
- Annan, Kofi, 301
- Ansari X Prize, 58
- “Anti-invent around” strategy, 176
- Antitrust law, 41, 283–284
- Apotex, 329
- Apple Computers
access to software, 231
formation of, 117, 152
innovation communities in, 98, 101
joint ventures, 158
mission statement, 139
screening of innovations, 228
trademarks, 75, 76
- Applera, 118
- Apple Records, 89
- Arbitration, comparative law re, 313
- Archon X Prize for Genomics, 59
- Arrow, Alexander, 219
- Arviso, Rosita, 108, 109
- Aspartame, 80, 175
- Aspirin, 19, 49
- Assessment of IP
external environment evaluation (*See* External environment evaluation)
failure to undertake, problems arising from, 184
internal asset evaluation (*See* Internal asset evaluation)
inward *versus* outward assessment, 184
overview, 184, 205–206
regular assessment, importance of, 184
- Assignment of IP rights
contracts, 269
employment contracts, in, 268
joint ventures, in, 268
licensing distinguished, 273–274
liens, 270
mergers, in, 268–269
noneconomic terms, 279
recordation of, 269, 270
security interests, 270
- Association of University Technology Managers, 34, 218, 298
- Atari, 151–152
- AT&T, 313
- Auctions
assignment of IP rights by, 269
IP assets, auctioning of, 219
- Australia
standards for obtaining patents, 310
volume of patents, 311
- Authorship, concept of, 73, 151
- Avian flu, 313, 330–331
- Awards as alternative to IP rights, 58–59, 343
- Bailment, 272
- Balanchine, George, 301
- Balancing access and exclusion
biodiversity and, 52
copyrights and, 45, 51
freedom and, 343
genetic resources and, 52
goals of IP management, as, 163–164
importance of, 45, 51
overview, 59
patents and, 45, 51
real property analogy, 45
tension between access and exclusion, 43–44
trademarks and, 45, 52
trade secrets and, 45, 52
- Bargaining chip strategy, 170–171
- Barr Laboratories, 178
- “Barter” agreements, 271
- Barton, John, 54
- Bavarian Nordic, 332
- Bayer, 49, 329
- Bayh, Birch, 34
- Bayh-Dole Act, 33–34
enactment of, 34
government licenses to patents under, 272
IARCs, applicability of model to, 204
Indian law, similarity of, 318
ownership of IP rights under, 270

Bayh-Dole Act (*cont.*)
 partnership model under, 33–34
 patent applications under, 203
 required licensing under, 158
 similar acts in other nations, 34
 universities, impact on, 34, 103, 297

Bell, Alexander Graham, 14

Benchmarking, 144

Benedict XVI, Pope, 106, 301

Benefit sharing agreements, 271

Berne Convention
 copyright protection under, 244
 historical background, 32
 moral rights under, 38, 275

Bill and Melinda Gates Foundation, 110, 299, 330

Biodiversity (*See* Convention on Biological Diversity)
 agreements, 271
 balancing access and exclusion and, 52
 biopiracy and, 311, 317, 319, 337

Biological materials
 access and benefit sharing agreements, 304
 balancing access and exclusion in, 52
 copyrights in, 292, 304
 IP rights in, 77
 material transfer agreements (MTAs), 272, 304
 patents in, 79, 292, 303–304
 plants (*See* Plants)
 quasi-IP rights, 304
 strategic IP management, 291–292
 trademarks in, 292–293, 304
 trade secrets in, 79, 292, 302

Biotechnology
 access, importance of, 338
 blocking rights in, 91
 criticism of, 337
 developing countries and, 55
 genetic sequences (*See* Genetic sequences)
 human rights considerations, 337
 innovators, position of, 336, 337
 IP, role of, 337–338
 moral considerations, 338
 open access and, 336
 patent disclosure requirements, 336–337
 political considerations, 336
 public interest advocates, position of, 336, 337

Bioversity International, 103

Bird flu (*See* Avian flu)

Blackberry
 customer interest in, 47, 118–119
 geographic scope of patents re, 232

IP management strategies and, 168
 licensing of patents, 277–278
 litigation re, 238, 261, 315
 patent protection, importance of, 293
 patent “trolls” and, 172
 valuation of IP assets and, 216–217, 222

Black-Scholes option pricing formula, 219–220

“Blanket” strategy, 173

Blocking rights
 bargaining chip, as, 237
 biotechnology, in, 91
 enforcement tool, as, 254
 infringement and, 91
 pharmaceuticals, in, 91

Bolar provisions, 314

Bowie, David, 214, 296, 324

Boyer, Herbert, 117

Branding, 179–180

Brazil
 AIDS medicines in, 128
 compulsory licenses in, 314
 negotiation, role of, 312
 patents, 311
 piracy in, 313
 examples of IP law, 317

“BRIC” countries, 316–317

Bristol-Myers Squibb, 209, 329

British Museum, 45

Brock, Thomas, 18

Broder, Sam, 178

Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Protection, 303

“Burning stick” strategy, 166–167

California, University of, 98, 102, 118, 203, 298

Cambridge University, 102

Canada
 compulsory licenses in, 314
 patents, volume of, 311

Canon, 293

Capetown, University of, 102

Cash value model for valuation. *See* Income-based valuation

CBD. *See* Convention on Biological Diversity

Celebrex, 328

Celera Genomics, 69, 109–110, 118

Challenging IP rights of others, 237–238

Index

393

- Charitable donations, sunk cost-based
valuation in, 213
- Chevron, 174
- Chiang Mai University, 102
- Chiefs. *See* Innovation chiefs
- “Chilling effect” of IP rights, 228–229
- China
Administration for Industry and Commerce,
318
Beijing Olympics, 205
examples of IP law, 318–319
negotiation, role of, 312
patents, volume of, 311
piracy in, 313
Public Service Bureau, 318
trademarks in, 311
- Choice and innovation, 342–343
- Christenson, Clayton, 101, 125, 128
- Churches. *See* Religious organizations
- CIPIH, report on pharmaceuticals and
developing countries, 55–56
- CIPR. *See* Commission on Intellectual Property
Rights
- Ciprofloxacin, 329
- Claritin, 175, 329
- Clean Air Act, 20
- Clean Water Act, 20
- Clickwrap licenses, 271
- Cluster theory of competition, 125–126
- Coca-Cola
exclusivity and, 254
IP thicket strategy, 168–169
trademarks, 74, 143, 251, 271
trade secrets, 67, 179, 244, 259, 267, 273, 290
- Cohen, Stanley, 117
- Co-inventors, 178
- Collaborators. *See also* Joint ownership
infringement and, 92
- Colleges. *See* Universities
- Collins, Frances, 14, 110
- Comedy, copyrights and, 301
- Commission on Intellectual Property Rights,
Innovation and Public Health (CIPIH),
report on pharmaceuticals and
developing countries, 55–56
- Commission on Intellectual Property Rights
(CIPR)
balancing access and exclusion, 51
developing countries, report re, 53–55
“one size fits all” approach, rejection of,
54–55
overview, 53–54
- Communities of innovation
common threads, 98
corporations, 101–102
developing countries (*See* Developing
countries)
differences between, 98
global innovation initiatives, 111–112
individuals (*See* Individuals and innovation)
- Internet as global innovation initiative,
111–112
- multinational research consortia (*See*
Multinational research consortia)
- nonprofit organizations (*See* Nonprofit
organizations)
- open innovation communities (*See* Open
innovation communities)
- overview, 97–98, 114
- political parties, 104–105
- regional innovation communities, 106–107
- religious organizations (*See* Religious
organizations)
- small businesses, 100–101
- small groups (*See* Small groups and
innovation)
- types of, 98
- universities, 102–103
- Comparative law. *See also specific country*
alternate dispute resolution, 313
arbitration, 313
compulsory licenses, 314
copyrights, standards for obtaining, 312
counterfeiting, 313
country to country variations, 309
criminal offenses, 314
developing countries, in, 319
enforcement of IP rights, 312–313, 314–315
language requirements, 310
mediation, 313
negotiating, 312
overview, 321
patents, 310–311
patterns of innovation, 309
piracy, 313
protection of innovation, 309
strategic IP management, 308–309
trademarks, standards for obtaining, 311–312
- Compulsory licenses
bargaining chip, as, 236
comparative law re, 314
generic drugs, 330
homeland security technology, 332
operation of law, transfer of IP rights by, 272

Computer programs. *See* Software

Confidentiality agreements

- employment contracts, in, 150
- entertainment industry, in, 295
- internal asset evaluation and, 196
- software and, 305–306
- trade secret theft and, 259

Consideration, 264–265, 269

Consultative Group on International Agricultural Research (CGIAR), 203–204

Consumer products and services

- copyrights in, 294
- labeling, 293–294
- strategic IP management, 293
- trademarks in, 294
- trade secrets in, 294–295

Contracts

- ABCD model and, 85
- assignment of IP rights, 269
- enforcement of IP rights, not necessary for, 85
- transfer of IP rights, 87

Convention on Biological Diversity (CBD)

- adoption of, 25
- balancing access and exclusion, 52
- bargaining under, 209
- environmental technology and, 334, 335
- historical background, 33
- involvement of new groups under, 56
- legal rights to biological materials under, 77
- licensing of genetic resources under, 272
- national sovereign rights under, 304
- traditional knowledge, protection of, 52, 78, 336, 337

Conversion to different type of IP, 79–81, 175

“Copyleft” licenses, 42, 112, 276 (*See also* Open access)

Copyright Act, 38, 301

Copyrights, 71–73

- authorship, concept of, 73
- balancing access and exclusion in, 45, 51
- Berne Convention, protection under, 244
- biological materials, in, 292, 304
- “chilling effect” of IP rights and, 229
- comedy and, 301
- comparative law re standards for obtaining, 312
- consumer products and services, in, 294
- conversion to different type of IP, 79–81
- dance and, 301
- electromechanical equipment, in, 305
- electronics, in, 293
- enforcement of, 259–260

- difficulty of, 73
- overview, 72–73
- prerequisites, 71–72

entertainment industry, in, 295–296

external environment evaluation (*See* External environment evaluation)

fair use of, 235

infringement, damages, 222

interactions with other types of IP, 78–79

internal asset evaluation re (*See* Internal asset evaluation)

life sciences, in, 292

maintenance, 250

music, in, 296

non-strategy model of IP management, effect of, 133

overview, 71, 83

ownership of, 267

piracy of copyrighted material, 73

portfolio management, 250–251

protection of innovation

- high level of investment, 245
- low level of investment, 245
- notice, importance of, 244–245

public domain

- dedication to, 250–251
- entry of copyrighted material into, 72

public speeches and, 301

registration, 250

religious organizations and, 106

rights of owners, 72–73

“self-help,” 73

software, in, 293, 306

strategic IP management, copyright-specific strategies, 181

sunk cost-based valuation, 212

symphony orchestras and, 300–301

table, 72

telecommunications, in, 293

theater and, 299–300

trade secrets, relationship with, 69

transfer of IP rights (*See* Transfer of IP rights)

TRIPS Agreement, protection under, 244

United Nations using, 202

universities and, 299

visionary model of IP management, effect of, 135–136

WHO using, 202

WIPO using, 202–203

Corporations

- innovation and, 101–102
- internal assets valuation in, 188, 189

Index

395

- management of innovation in, 126–127
- ownership of IP rights distinguished from
 - ownership of corporations, 268
- strategic IP management, 290
- valuation of IP assets in, 208
- Cost-based valuation, 211–214
 - replacement cost, 213–214
 - sunk cost
 - advantages, 213
 - charitable donations, 213
 - copyrights, 212
 - disadvantages, 213
 - illustrations, 212–213
 - overview, 211–212
 - patents, 212
 - trademarks, 212
 - trade secrets, 212
- Cost management, 159–161
 - counsel, hiring of, 160
 - deciding what assets to protect, 159
 - human resource management, importance of, 159–160
 - leadership, importance of, 160–161
 - organizational management, importance of, 160
 - variation in costs, 159
- Counterfeiting, comparative law re, 313
- Creative Commons, 172, 182, 276
- “Creative construction,” 57–58, 124
- Creative destruction
 - freedom and, 344
 - management of innovation, applied to, 122, 125
 - Schumpeter on, 11–12, 19
- Crick, Francis, 303
- Criminal offenses, 314, 317, 319
- Criticism of IP, 40–43
 - competition, promotion of, 42
 - cost of obtaining and maintaining, 42
 - cost of technology, increasing, 41
 - inappropriate concentration of industry, 42
 - legal and regulatory framework, requirement of, 42
 - monopolies, creation of, 41
 - moral objections, 43
 - overview, 36–37, 40, 59
 - procurement practices, overcoming through, 155–156
 - public domain, keeping innovation out of, 40
- Cross-license agreements, 271
- Customers and infringement, 93–94
- Dali, Salvador, 18
- Dance, copyrights and, 301
- Databases, 77, 79
- Davila, Tony, 124, 125, 128
- da Vinci, Leonardo, 123
- DC Comics, 79, 297
- DDT, 20
- Dealing in IP rights. *See* Transfer of IP rights
- Definitions of IP, 22–23
 - accounting definition, 23
 - dictionary definition, 22–23
 - legal definition, 23
 - management definition, 23
 - scholarly definition, 23
- Dell Computers, 171, 280
- Delta Faucet Company, 175
- “Designing around” patents, 234
- Design patents, 71
- Developing countries. *See also specific country*
 - agriculture and, 55, 107–108
 - biotechnology and, 55
 - CIPR report, 53–55
 - external environment evaluation, 203
 - innovation in, 107–109
 - access to IP professionals, lack of, 109
 - authoritarian governments, problem of, 108
 - collaboration with other organizations, 109
 - importance of, 109
 - obstacles to, 108
 - overview, 107
 - poverty, problem of, 108
 - traditional knowledge and, 108–109
 - IP law in, 319
 - patterns of innovation in, 309
 - pharmaceuticals and, 55
 - CIPRH report, 55–56
 - tension re IP system in, 53–56
 - enforcement issues, 53
 - Eurocentric nature of IP system, 53
 - overview, 53
 - trademarks and, 108
 - TRIPS Agreement, lack of full implementation of, 309
- Diamond, Jared, 14, 15
- Digital Maoism, 43
- Digital Millennium Copyright Act of 1998, 297
- Dinwoodie, Graeme B., 48
- Doha Declaration, 314
- Domain names, 76, 112, 313
- “Do-nothing” organizations, converting, 165
- Dove-Edwin, Beatrice, 320

Dreamworks, 324
 Dreyfuss, Rochelle Cooper, 48
 Drucker, Peter
 corporations, on management of innovation
 in, 127
 “creative construction” concept and, 124
 creative destruction concept and, 122
 government planning, on role of, 124
 innovation communities, on, 101
 IP management, on, 124
 management of innovation, on, 122–124
 new and old ventures, on separating, 124
 sources of innovation, on, 122, 123, 128
 universities, on, 102
 Drugs. *See* Pharmaceuticals
 Due diligence in external environment
 evaluation, 198, 199–200
 Duration of IP rights, limits on, 232
 Dynamic conceptual framework of IP rights, 63,
 96
 Dynamic innovation theory, 41

 East Coast Fever vaccine project, 109
 Eastman Kodak, 75, 119, 208, 238, 251, 261, 315
 eBay, 140
 Edison, Thomas, 14, 100, 124
 Egypt
 criminal offenses in, 314
 overview of IP in, 26–28
 Eisenberg, Rebecca, 44
 Electromechanical equipment
 copyrights in, 305
 integrated circuits, 305
 licensing of IP rights, 305
 patents in, 305
 strategic IP management, 304–305
 trademarks in, 305
 Electronics
 copyrights in, 293
 patents in, 293
 strategic IP management, 293
 trademarks in, 293
 trade secrets in, 293
 Emory University, 189, 215, 221, 324
 Employee rights, 77
 Employment (*See also* Personnel practices)
 internal asset evaluation, issues in (*See*
 Internal asset evaluation)
 key employees new job, 51
 infringement and, 92
 personnel practices (*See* Personnel practices)
 Employment contracts, 150, 196, 268

End user license agreements (EULAs), 271,
 307
 Endy, Drew, 304
 Enforcement of IP rights
 blocking rights, 254
 comparative law re, 312–313, 314–315
 confronting infringers, 159
 control of rights and, 254
 copyrights, 259–260
 difficulty of, 73
 overview, 72–73
 prerequisites, 71–72
 costs, 254
 exchange of rights for value, 254
 external environment evaluation and,
 201–202
 historical background, 253
 importance of, 253–254
 licenses, 281
 litigation and, 159, 254
 monitoring, 158–159
 notice of rights, importance of, 158
 other rights, 261
 overview, 158, 162, 255, 262
 patents, 260–261
 “sleeping on rights,” 159
 strategic IP management, in, 158–159
 tension regarding, 53
 trademarks, 75, 260
 trade secrets, 68, 257–259
 Enforcement triage
 decision-making, 257
 infringement analysis
 infringement, 257
 validity, 257
 overview, 255
 threshold questions, 255–257
 English law, IP under, 25, 29–30
 Entertainment industry
 confidentiality agreements, 295
 copyrights in, 295–296
 music (*See* Music)
 patents in, 295
 public performances (*See* Public
 performances)
 strategic IP management, 295
 trademarks in, 297
 trade secrets in, 295
 Entertainment licenses, 270
 Environmental technology
 benefits of, 334
 complexity of, 333, 335–336

Index

397

- environmental impact, consideration of, 333–334
- IP, role of, 334–335
- market forces, promotion via, 334
- overview, 333
- patents in, 335
- technology-forcing regulations, 334
- technology transfer, role of, 335
- trademarks in, 335
- trade secrets in, 335
- US, environmental regulation in, 333
- Eolas, 315
- Established royalty rates, use in valuation, 220
- EU Database Directive, 77
- European Commission, 315
- European Patent Convention, 33
- European Patent Office (EPO), 310, 311, 315
- European Union (EU)
 - community trademarks in, 245, 316
 - summary of IP law, 315–316
- Evaluation of IP
 - external environment evaluation (*See* External environment evaluation)
 - internal asset evaluation (*See* Internal asset evaluation)
- Exclusion from innovation
 - balancing with access (*See* Balancing access and exclusion)
 - exclusivity, 279, 343
- External environment evaluation
 - copyrights
 - assets, 201
 - exclusivity, 201
 - freedom to operate, 201
 - developing countries, 203
 - due diligence, 198, 199–200
 - enforcement of IP rights and, 201–202
 - failure to undertake, problems arising from, 199
 - governmental agencies, 202–203
 - internal asset evaluation, relationship to, 187
 - issues to be addressed, 185
 - litigation, obtaining information in, 198
 - negotiation, obtaining information in, 198
 - nonprofit organizations, 202–203
 - patents, 200
 - assets, 200
 - exclusivity, 200
 - freedom to operate, 200
 - sources of information, 198
 - trademarks, 200
 - assets, 200
 - exclusivity, 200–201
 - freedom to operate, 201
 - trade secrets
 - assets, 201
 - exclusivity, 201
 - freedom to operate, 201
 - widespread availability of information, 198–199
- Fairness and innovation, 344
- Fair use, 235–236
 - copyrights, of, 235
 - overview, 235
 - patents, of, 235–236
 - trademarks, of, 235
 - trade secrets, of, 236
- “Fence” strategy, 173
- Fictional characters, 79, 297
- Field of use, 279–280
- File reproduction technology, 56, 296–297
- “First one’s free” strategy, 172
- First sale doctrine, 229–231
- 5% rule in valuation, 220–221
- “Flood” strategy, 173
- Flow of IP rights. *See* Transfer of IP rights
- Food and Agriculture Organization, 103
- Food and Drug Administration (FDA), 80, 215, 216
- Ford Motor Company, 174
- Forest analogy, 81–82
- Forest strategy, 169–170
- Franchises
 - licenses, 271
 - partnering practices and, 157–158
- Freedom and innovation
 - balancing access and exclusion, 343
 - choice and, 342–343
 - creative destruction, 344
 - exclusivity, effect of, 343
 - expansion of, 342
 - fairness and, 344
 - Lincoln on, 343–344
- Freedom to operate analysis, 228, 235
- Friedman, Tom, 13
- Gallo, Robert, 14
- Gates, Bill, 100
- G.D. Searle, 80, 175
- GenBank, 67, 182
- Genentech, 98, 117
- General Electric, 113
- General Motors, 152, 259

- Generic drugs *versus* branded drugs
 balancing of interests, 326, 330, 331
 compulsory licenses, 330
 economic arguments, 326
 examples of, 328–329
 false dichotomy, 328
 globalization of generic industry, 330
 incentives for generic companies, 328
 “medicine here *versus* medicine elsewhere,”
 329–330
 “medicine now *versus* medicine later,”
 326
 overview, 325
 patent expiration, impact of, 328
 pharmaceutical “ecosystem” and, 326
 populist arguments, 326
 public-private partnerships, 330
 public research *versus* private research,
 326–328
- Genetic sequences
 open innovation communities and, 113
 patents, 79
 procurement practices and, 154–155
 trade secrets in, 302–303
- Geographical indications, 76–77
- Geographical scope of IP rights, limits
 on, 232
- Georgia-Pacific factors, 218–219
- Germany
 Blaue Engel program, 335
- Glaxo Smith Kline, 329
- Glazier, Stephen, 173, 175
- Global challenges, 341
- Global Forum for Health Research, 42
- Global Fund to Fight AIDS, Tuberculosis and
 Malaria, 111
- Global innovation initiatives, 111–112
- GNU Free Documentation License, 276
- Goals of IP management
 ad hoc decisions, avoiding, 139
 balancing access and exclusion, 163–164
 communication of, 139–140
 consistency of, 141
 control, increasing, 140
 defining, 139–141
 for-profit companies, relevance to, 164
 list of general goals, 164
 long-term *versus* short-term results, 140–141
 mission statements, 139
 nonprofit organizations, relevance to, 164
 social goals distinguished, 163
- Goodwill, 142
- Google
 copyrights and, 135–136
 extra value in product, 140
 internal IP assets, evaluation of, 188–189
 scanning of books by, 251
- Gould, Gordon, 14, 99, 176
- Governmental agencies
 evaluation
 copyrights, 202–203
 overview, 202
 patents, 203
 trademarks, 203
 trade secrets, 202
 homeland security technology, access to, 332
 license rights, 272
 strategic IP management, 297
 valuation of IP assets, 222–223
- Government use of innovations of others,
 236–237
- Granting clauses, 279
- Grants as alternative to IP rights, 58–59, 343
- Greece, IP in, 28
- Guei, Robert, 108
- Guinness, 244, 290
- Gupta, Anil, 57, 98
- Haiti, summary of IP law, 319
- Hardin, Garrett, 44
- Harrison, George, 259–260
- Hatch-Waxman Act, 284, 328
- Heller, Michael, 44
- Hewlett-Packard, 293
- Historical background of IP, 22–35
 Bayh-Dole Act (*See* Bayh-Dole Act)
 diversity of, 26
 dynamic view of, 25–26
 early treaties, 32
 Egypt, in, 26–28
 emergence of social institutions and, 26
 English law, 25, 29–30
 Greece, in, 28
 Industrial Revolution, during, 31–32
 innovation, relationship with, 24
 Jewish law, 28
 lack of public disclosure, impact of, 28
 Lincoln on, 28–29
 Middle Ages, during, 28
 modern treaties, 32–33
 natural law concepts, 24
 overview, 24, 26, 34–35
 philosophical debate re, 32
 Rome, in, 28

Index

399

- special nature of IP system, 24
- trademark concepts, 28
- US Constitution, 24–25
- Venetian Patent Decree of 1474 (*See* Venetian Patent Decree of 1474)
- Hitachi, 293
- Hitler, Adolf, dark side of innovation and, 20
- HIV medicines
 - Brazil, in, 128
 - conversion to different type of IP, 79
 - public domain and, 47
 - unnamed co-inventors and, 178
- Holding companies, 157
- Homeland security technology
 - balancing of interests, 332–333
 - compulsory licenses, 332
 - expedited patent process, 331–332
 - governmental agencies, access by, 332
 - innovation, role of, 331
 - IP management strategies, 331
 - trade secrets in, 332
- “Homesteading” strategy, 172–173
- Honda, 293
- Honeybee Network, 57, 98
- Hu Jintao, 319
- Human genome, trade secrets and, 69
- Human Genome Project, 69, 109, 110
- “Hurdle” strategy, 174
- Hybrid methods of valuation, 218–220
- Hypothetical royalty negotiations, valuation by, 218–219
- IBM
 - IP portfolio of, 41, 143
 - open access and, 182
 - open peer review, 113
 - patents
 - cross-licensing of, 171
 - licensing of, 136, 277
 - volume of, 118, 293
 - trademark protection, 293
- ICICI, 324
- ICRISAT, 108
- Igen, 208, 217, 222, 238
- Imhotep, 13
- Implementation of strategic plan, 145–146, 226–227
- Implied licenses, 271
- Improvements, 281
- Income-based valuation
 - advantages, 214–215
 - decision trees, use of, 215, 216
 - disadvantages, 215
 - discounted cash flow, calculation of, 214, 216
 - illustrations, 214, 215–216
 - net present value, calculation of, 214, 216
 - overview, 214
 - projected sales volume, importance of, 216
 - relief from royalty model, 217
 - time, importance of, 216
- Indemnity, 281–283
- India
 - Bayh-Dole Act, similarity of law to, 318
 - compulsory licenses in, 314
 - examples of IP law, 317
 - pharmaceutical industry in, 40
 - piracy in, 313
 - Traditional Knowledge Digital Library, 318
 - TRIPS Agreement, laws adopted in
 - compliance with, 117
- Indian Institute of Technology, 26
- Indian National Innovation Foundation, 99
- Individuals and small groups and innovation, 98–100
 - Bangladesh, in, 99
 - disadvantages of, 99–100
 - downplaying role of, 14
 - India, in, 98–99
 - overview, 98
 - successful models, 100
 - US, in, 99
- Indonesia, piracy in, 313
- Industrial Revolution, IP during, 31–32
- Infringement, 92–94
 - “accessible domain” and, 91
 - blocking rights, 91
 - collaborators and, 92
 - confronting infringers, 159, 167
 - copyrights, damages, 222
 - customers and, 93–94
 - infringing path, 93
 - internal activities, use of IP for, 92–93
 - key employees and, 92
 - liability for, 93
 - non-infringing path, 93
 - organizational level, at, 92
 - overlapping rights and, 91
 - overview, 95–96
 - patents
 - damages, 222
 - defenses, 70
 - remedies, 70
 - procurement practices, effect on, 155
 - trademarks, damages, 222

- Infringement (*cont.*)
 trade secrets, damages, 222
 two-way nature of, 92, 94
- Innovation
 access to (*See* Access to innovation)
 communities of (*See* Communities of innovation)
 competition and, 14
 complexity of, 15
 creative destruction and, 11–12
 developing countries, in (*See* Developing countries)
 drawbacks of, 20–21
 difficulty in regulating, 21
 environmental problems, 20
 nanotechnology, 20–21
 overview, 20
 political problems, 20
 economic factors influencing, 15
 freedom and (*See* Freedom and innovation)
 “heroic theory” of, 13–14
 historical background, 12–13
 homeland security technology, role in, 331
 individuals and (*See* Individuals and innovation)
 IP, relationship with, 12, 15, 24, 53, 94–95
 law, impact of, 14–15
 management of (*See* Management of innovation)
 overview, 11, 21
 personal *versus* social level, 15
 precautionary principle and, 20
 protection of (*See* Protection of innovation)
 reasons for, 13–15
 securitization of IP rights, impact of, 325
 self-interest and, 13
 social demand for, 13
 societal ability to adopt, 14
- Innovation chiefs
 corporate hierarchy, in, 115–116
 damage caused by, 118–119
 effectiveness of, 118
 enabling of creativity, 117
 human stories behind, 116–118
 innovation teams, necessity of, (*See also* Innovation teams), 116
 leadership, importance of, 116–119
 overview, 115, 128
 power struggles involving, 118
 questions addressed by, 116
 “real world” dimension of, 116
 reliance on, 117
 titles of, 115–116
 types of, 115–116
- Innovation cycle, 15–19, 63, 81, 82, 98, 103
 accessibility stage, 18–19
 circular model, 16
 creative destruction and, 19
 creative work stage, 17–18
 diffusion stage, 18
 dynamics, 46, 58, 59, 64, 94–95, 299, 325, 340
 enforcement and, 254
 flow of IP rights and, 84, 263, 285
 forest analogy, 81–82
 individuals and, 100, 344
 innovation chief and, 116, 147
 linear model, 15–16
 overview, 15
 patents and, 71, 179
 public domain, effect on, 46
 trade secrets and, 80
 valuation and, 224
- Innovation forest metaphor, 81–82
- Innovation teams, 119–122
 background of members, 119–120
 business experts, 120–121
 creativity experts, 120
 globalization, impact of, 121–122
 legal experts, 120
 necessity of, 116
 outsourcing of, 121
 overview, 128
 senior management members, 121
 structure of teams, 121
 usefulness of, 119
- Innovation tree metaphor, 64
 country-to-country differences, 65–66
 new information and, 64–65
 types of IP rights, 66 (*See also specific topic*)
- Innovation triage, 240–242
 high level of investment, 240
 imminent loss of rights, threat of, 242
 low level of investment, 240–242
 no investment, 242
 overview, 240
 portfolio management, in, 248–249
 timing considerations, 242
- Institute for Genomics Research, the, 103, 109
 (*See* J. Craig Venter Institute)
- Institute for One World Health, 299
- Integrated circuits, 305
- Intel, 278, 293, 305
- Intellectual asset management (IAM), 126–127
- Intellectual capital management (ICM), 126–127

Index

401

- Intellectual Property Owners Organization, 293
- Intellectual Ventures, 118, 136
- Interactions between types of IP, 78–79
- Interdisciplinary dynamic approach to IP, 12
- Intergovernmental Panel on Climate Change, 335
- Internal activities, use of IP for, 92–93
- Internal asset evaluation
 - agreements, 197–198
 - basic steps, 186–187
 - benefits of, 189
 - commercial enterprises, in, 188, 189
 - common IP-generating activities, 188
 - copyrights, 194–195
 - applied for, 194
 - categories of works, listing, 194
 - internal procedures, review of, 195
 - outsiders, works created by, 194–195
 - software licensing issues, 195
 - deciding what to protect, 187
 - different methods, 186
 - difficulty of, 185–186
 - employment issues, 196–197
 - confidentiality agreements, 196
 - employment contracts, 196
 - noncompetition covenants, 196
 - outsider information, use of, 196–197
 - external environment evaluation,
 - relationship to, 187
 - issues to be addressed, 185
 - licenses, 197–198
 - listing registered IP rights, 186
 - nonprofit organizations, in, 188
 - overlapping concerns, 189
 - patents, 192–193
 - coordinators, role of, 193
 - counsel, role of, 192, 193
 - internal procedures, review of, 193
 - invention disclosure requirements, review of, 193
 - IP managers, role of, 192
 - owned or applied for, 192–193
 - peripheral individuals, 192
 - potential infringement, discovering, 193–194
 - process review, 186–187
 - questionnaire re, 189–192
 - categorization, 190–192
 - comprehensive questionnaires, 190
 - confidentiality, 190
 - counsel, role of, 190
 - dissemination of, 190
 - overview, 189–190
 - sample, 375 (*See* Appendix C)
 - short questionnaires, 190
 - scope of, 187–189
 - tailoring of, 187–188
 - timing issues, 185–186
 - trademarks, 194
 - internal procedures, review of, 194
 - nonregistered names, listing, 194
 - overview, 194
 - potential infringement, discovering, 194
 - registered trademarks, listing, 194
 - trade secrets, 195–196
 - continuing evaluation, 196
 - disclosures of confidential information,
 - identifying, 195–196
 - outsider information, use of, 196
 - overview, 195
 - prioritizing confidential information, 195
 - process audit approach, 195
 - universities, in, 189
- Internal Revenue Service, 213
- International agricultural research centers (IARCs), 203–204
- International Association for the Study of Common Property, 52
- International Center for Agricultural Research, 170
- International Chamber of Commerce, 313
- International Livestock Research Institute, 103, 109
- International Trade Commission (ITC), 332
- International Treaty on Plant Genetic Resources for Food and Agriculture
 - balancing access and exclusion, 52
 - historical background, 33
 - open access under, 272
- International Union for the Protection of New Varieties of Plants (UPOV)
 - developing countries and, 55
 - historical background, 33
 - plant patents under, 71
- Internet
 - clickwrap licenses, 271
 - global innovation initiative, as, 111–112
- Internet Corporation for Assigned Names and Numbers (ICANN), 111
- “Invent around” strategy, 175–176
- Invisible infrastructure of innovation, 1–3
- iPod, 117, 139, 228, 297

Irtisen, 26–28, 67, 253
 Israel, piracy in, 313
 iTunes, 117, 139, 228, 277, 297

J. Craig Venter Institute, 103, 109, 113, 303

Japan
 Bolar provisions in, 314
 patents
 standards for obtaining, 310
 volume of, 311
 summary of IP law, 316

Jefferson, Thomas, 25, 178

Jewish law, IP under, 28

Jobs, Steve
 Apple Computers and, 117
 independent inventor, as, 100
 innovation by, 117

Johns Hopkins University, 298

Johnson & Johnson, 251

Joint ownership, 87–90
 assignment *versus* licensing, 273
 combining different types of IP, 88–89
 discrete parts, allocation of rights to, 89
 exclusive rights, lack of, 88
 overview, 87–88, 95–96
 public domain, rights dedicated to, 89
 pure joint ownership, 89
 sharing different types of IP, 89
 third party, transfer of rights to, 89
 transfer of IP rights, 89–90

Joint ventures, 158, 268, 277

Jones, Monty, 107, 108

Katz, Ronald, 277

Kearns, Robert, 99

Kenya, summary of IP law, 320–321

Kilby, Jack, 14

King, Martin Luther, Jr., 301

Knight, Jackson, 173

Knowledge-based innovation, 123

Korea
 compulsory licenses in, 314
 patents, volume of, 311
 summary of IP law, 319

Kyoto Protocol, 335

Lemelson, Jerome, 99, 177

Lennon, John, 87, 89

Letters patent, 69

LG Industries, 319

Library of Congress, 269, 273

Licensing of IP rights

advantages of
 business resources of licensee, leveraging, 277
 geographic reach, broadening, 277
 market penetration, increasing, 277
 revenue stream, creating, 277–278
 underlying ownership interest, maintaining, 277

antitrust law and, 283–284

assignment distinguished, 273–274

bailment, 272

“barter” agreements, 271

benefit sharing agreements, 271

biodiversity agreements, 271

clickwrap licenses, 271

complexity of, 284

compulsory licenses (*See* Compulsory licenses)

“copyleft” licenses, 42, 112, 276

cross-license agreements, 271

disadvantages of
 control, loss of, 278
 dependency on others for revenue, 278
 incentive, loss of, 278
 innovation, stopping of, 278
 IP rights, risk of loss of, 278
 recognition, loss of, 278

duration, 280

economic terms, 283

electromechanical equipment, 305

end user license agreements (EULAs), 271, 307

enforcement, 281

entertainment licenses, 270

exclusivity, 279

field of use, 279–280

foreign universities, 298–299

franchise licenses, 271

governmental agencies, rights of, 272

granting clauses, 279

illegal transfers, 272–273

implied licenses, 271

improvements, 281

indemnity, 281–283

joint ventures and, 277

material transfer agreements (MTAs), 272

noneconomic terms, 279

open access licenses, 271, 275–276

operation of law, by, 272

overview, 270, 271

publishing licenses, 270

recordation of, 273

Index

403

- royalties, 283
- shrinkwrap licenses, 271
- software (*See* Software)
- sublicenses, 271, 280
- tangible property, effect of transfer of, 271–272
- technology licenses, 270
- termination clauses, 280–281
- territory, 280
- trademark licenses, 270–271
- transferability, 280
- warranties, 281–283
- Liens, 270
- Life sciences. *See also* Biological materials; Pharmaceuticals
 - strategic IP management, 291–292
- Lincoln, Abraham
 - “fire of genius,” 29, 343
 - innovation, on, 343, 344
 - IP, on, 32, 344
 - patents, on, 28, 29, 31, 32, 343
- Linux
 - access to software, 140, 231
 - open source software and, 112, 157, 181, 182
 - trade secrets, 293
- Lipitor, 117, 292
- Locke, John, 38
- Lopez de Arriortua, Jose Ignacio, 152, 259
- Loratidine, 329 (*See* Claritin)
- Madrid Protocol
 - historical background, 32
 - trademarks under, 245, 316
- Major League Baseball, 208
- Makerere University, 102
- Management of innovation, 122–128
 - Christenson on, 125
 - cluster theory of competition and, 125–126
 - corporations, in, 126–127
 - “creative construction” concept and, 124
 - creative destruction concept and, 122, 125
 - Davila on, 124–125
 - Drucker on, 122–124
 - government planning, role of, 124
 - intellectual asset management (IAM), 126–127
 - intellectual capital management (ICM), 126–127
 - IP management, importance of, 124, 125
 - knowledge-based innovation, 123
 - new and old ventures, separating, 124
 - outside of corporations, 127–128
 - overview, 122, 128
 - Porter on, 125–126
 - practical advice, 123–124
 - sources of innovation, 122–123
 - technical innovation *versus* business innovation, 124–125
- Management of IP. *See* Strategic IP management
- Market-based valuation
 - advantages, 218
 - disadvantages, 218
 - illustrations, 217–218
 - overview, 217
- Martial, 28
- Marvel Comics, 297
- Massachusetts Institute of Technology, 203, 304
- Material transfer agreements (MTAs) 272, 304 (*See* Biological Materials)
- Maverick, Samuel, 180
- Max, Peter, 188
- McCartney, Paul, 87, 89
- McDonald’s, 157, 217, 294
- Mediation, comparative law re, 313
- Medicine. *See* Pharmaceuticals
- Merck, 140, 328
- Mergers, 268–269
- Merial, 109
- Mexico
 - examples of IP law, 320
- MGM, 39
- Michelangelo, 18
- Mickey Mouse, 79
- Microsoft
 - access to software, 231
 - copyright licenses, 112
 - enforcement of IP rights, 313
 - infringement, damages for, 315
 - innovation, impact of, 11
 - joint ventures, 158
 - Office suite, 158
 - open peer review, 113
 - open source software and, 182
 - trademarks, 293
- Middle Ages, IP during, 28
- Minimalist strategy, 165–166
- Mission statements, 139
- Monetizing of IP assets, 223
- Monopolies
 - creation of as criticism of IP, 41
 - IP rights contrasted, 254–255
- Monsanto, 80
- Montagnier, Luc, 14
- Moral rights, 38, 39, 275

“Move quickly and hold on” strategy, 180

Mullis, Kary, 18

Multinational research consortia, 109–111

- benefits of, 111
- competition, effect of, 109–110
- examples of, 109
- product development partnership model, 110–111

Music

- access to innovation, 231
- copyrights in, 296
- digital, 296–297
- file reproduction technology in, 56, 296–297
- public domain and, 47
- symphony orchestras
 - copyrights and, 300–301
 - importance of IP rights to, 300
- trademarks in, 297

“Mutual assured destruction” strategy, 171–172

Myhrvold, Nathan, 118, 136

MySpace, 113

Nanotechnology, 20–21

National Cancer Institute, 178, 329

National Center for Biotechnology Information, 208

National Institutes of Health

- access to research tools, 222
- databases, 182
- development of pharmaceuticals by, 329
- licensing of pharmaceuticals by, 178, 209
- patent portfolio, 298
- publication by, 208
- research by, 103
- sunk costs, 212

Natural law concepts of IP, 24, 38–39

NCAA, 208

Nebhepetra Mentuhotep, 26, 253

Need for shared framework, 3–4

Negotiation. *See* Transfer of IP rights

Net present value, calculation of, 214, 216

New Rice for Africa (NERICA), 108

Newton, Isaac, 15

New York Intellectual Property Law Association, 254

New York Times, 275

NeXT Computers, 117

Nike, 170

Noncompetition covenants, 150, 196

Nonprofit organizations

- advocacy and, 103
- external environment evaluation

- copyrights, 202–203
- overview, 202
- patents, 203
- trademarks, 203
- trade secrets, 202

funding of, 103–104

innovation and, 103–104

internal assets valuation in, 188

IP management, 104

overview, 103

partnering practices, 158

product development partnerships, 299

protection of innovation in, 239–240

publication by, 297, 298

purposes of, 104

strategic IP management, 297

trade secrets and, 297

types of institutions, 103

valuation of IP assets in, 208–209

Norway, compulsory licenses and, 314

Novartis, 328

Noyce, Robert, 14

NTP (*See* Blackberry)

Nutrasweet, 80

Ocean Tomo, 219, 269

Olympics (Beijing), 205

Open access

- ABCD model of transfer of IP rights, 181, 182
- balancing access and exclusion, 52
- biotechnology and, 336
- expanding access by assertion of IP rights, 181
- growth of, 182
- licenses, 271, 275–276
- Linux model, 181
- overview, 182
- plants, 272
- public domain distinguished, 113, 181–182
- publishing, in, 182
- underlying IP rights as basis of, 181

Open innovation communities, 112–113

- genetic sequences and, 113
- media and, 112–113
- open peer review, 113
- open source software, 112
- public domain distinguished, 113
- Wikipedia as, 112

Open source software

- innovation community model, 112
- Linux (*See* Linux)
- partnering practices, 157

Index

405

- Organization for Economic Cooperation and Development, promotion of innovation by, 34
- Ownership of IP rights
- corporate ownership distinguished, 267–268
 - different types of IP contrasted, 267
 - joint ownership (*See* Joint ownership)
 - public domain and, 267
 - tangible property ownership distinguished, 268
 - terminology of ownership, 267
- Oxford English Dictionary, 22
- Pan American World Airways, 251
- Panti, Don Eljio, 108
- Parallel imports (gray market), 318
- Paris Convention
- applications under, 252
 - historical background, 32
 - patent protection under, 247
- Partnering practices, 156–158
- affiliates, 157
 - franchises, 157–158
 - holding companies, 157
 - joint ventures, 158
 - nonprofit organizations, 158
 - open source software, 157
 - partnerships, 158
 - service contracts, significance of, 156–157
 - strategic alliances, 158
- Patent and Trademark Office (UK), 321
- Patent and Trademark Office (US)
- assignments, recordation of, 269, 270
 - disclosures to, 199
 - independent inventors and, 99
 - licenses, recordation of, 270
 - open peer review process, 113
 - public databases, 223
 - streamlining of processes, 315
- Patent Cooperation Treaty (PCT)
- applications under, 247, 252, 311
 - historical background, 33
 - patent protection under, 247
 - Sierra Leone and, 320
 - WIPO administration of, 32
- Patent License Exchange, 219
- Patents, 69–71
- abandonment, 253
 - applications for, 69–70, 252
 - balancing access and exclusion in, 45, 51
 - biological materials, in, 79, 292, 303–304
 - biotechnology, disclosure requirements, 336–337
 - broader claims, pursuing, 252
 - comparative law
 - standards for obtaining, 310–311
 - volume of, 311
 - conversion to different type of IP, 79–81, 175
 - counting, valuation by, 223
 - “designing around,” 234
 - design patents, 71
 - electromechanical equipment, in, 305
 - electronics, in, 293
 - enforcement of, 260–261
 - entertainment industry, in, 295
 - environmental technology, in, 335
 - exceptions, 246
 - expiration, 70
 - external environment evaluation (*See* External environment evaluation)
 - fair use of, 235–236
 - fees, 69
 - foreign applications, 252–253
 - foreign universities and, 298–299
 - homeland security technology, expedited process for, 331–332
 - infringement
 - damages, 222
 - defenses, 70
 - remedies, 70
 - interactions with other types of IP, 78–79
 - internal asset evaluation re (*See* Internal asset evaluation)
 - invention disclosure requirements, 246–247
 - inventiveness element, 71
 - letters patent, 69
 - life sciences, in, 292
 - loss of rights, 70
 - non-strategy model of IP management, effect of, 133–134
 - obtaining, 69–70
 - overview, 69, 83
 - ownership of, 267
 - parallel protection, 247
 - Paris Convention, protection under, 247
 - patent “jiu jitsu,” 175
 - patent pending, 69
 - patent thickets, 169
 - patent traps, 174
 - patent “trolls,” 155, 171–172, 325
 - perfecting applications, 253
 - pharmaceuticals, in, 292
 - plants, in, 71

- Patents (*cont.*)
- portfolio management, 252–253
 - protection of innovation (*See* Protection of innovation)
 - provisional applications, 247
 - “pruning” of, 252
 - publication of, 70
 - reexamination requests, 178
 - right to exclude, 70–71
 - software, in, 293, 306
 - strategic IP management, patent-specific strategies, 172
 - “submarine” patents, 176–177
 - sunk cost-based valuation, 212
 - table, 70
 - telecommunications, in, 293
 - trade secrets, relationship with, 69
 - transfer of IP rights, 274–275
 - TRIPS Agreement
 - consistency of, 310
 - fair use under, 236
 - protection under, 246
 - uncited prior art, 178
 - universities and, 297–298
 - unnamed co-inventors, 178
 - utility patents, 70
 - Venetian Patent Decree of 1474 (*See* Venetian Patent Decree of 1474)
 - visionary model of IP management, effect of, 136
- Paxil, 329
- PCT. *See* Patent Cooperation Treaty
- Penicillin, 19, 123
- PepsiCo, 273, 317
- Personnel practices 149–152 (*See also* Employment)
- authorship, concept of, 151
 - confidentiality agreements, 150
 - employment contracts, 150
 - internal *versus* external IP rights, 150
 - invention disclosure requirements, 151
 - noncompetition covenants, 150
 - overview, 149–150, 162
 - recruitment, during, 150–151
 - review of, 152
 - termination, during, 152
- Petrash, Gordon, 126
- Pfizer
 - challenging patents of, 117, 292, 319
 - generic drugs *versus* branded drugs, 328
 - innovation communities in, 101
 - trademarks, 292
- Pfizer, Charles, 100
- Pharmaceuticals
 - access to innovation, 231–232
 - AIDS medicines
 - Brazil, in, 128
 - conversion to different type of IP, 79
 - public domain and, 47
 - unnamed co-inventors and, 178
 - antitrust law and, 284
 - blocking rights in, 91
 - copyrights and, 292
 - developing countries and, 55
 - CIPIH report, 55–56
 - generic drugs *versus* branded drugs (*See* Generic drugs *versus* branded drugs)
 - India, pharmaceutical industry in, 40, 317–318
 - IP thicket strategy, 169
 - patents and, 292
 - product development partnerships, 299
 - strategic IP management, 291–292
 - trademarks and, 292–293
 - trade secrets and, 292
 - trends in IP system re, 56
- PIIPA. *See* Public Interest Intellectual Property Advisors
- Piracy
 - comparative law re, 313
 - copyrighted material, of, 73
- Piracy of copyrighted material, 73
- Pixar Studios, 117
- Pizza Hut, 157
- Plants
 - access to innovation, 231
 - International Treaty on Plant Genetic Resources for Food and Agriculture (*See* International Treaty on Plant Genetic Resources for Food and Agriculture)
 - open access to, 272
 - patents in, 71
 - UPOV (*See* International Union for the Protection of New Varieties of Plants)
- Polaroid, 119, 208, 238, 261, 315
- Policing. *See* Enforcement of IP rights
- Policy for IP management, 148–149
 - communication of, 149
 - overview, 162
 - policy statements, 148–149

Index

407

- review of, 149
 - triggering events, 149
- Political parties and innovation, 104–105
- Porter, Michael, 106, 125–126, 128
- Portfolio management
 - affirmative steps to protect IP rights, 153
 - categorization of assets, 248
 - common elements, 153
 - communication, channels of, 153
 - copyrights, 250–251
 - evaluation, 153
 - forestry analogy, 248
 - innovation triage in, 248–249
 - monitoring, 153
 - overview, 152–153, 162, 248, 262
 - patents, 252–253
 - regularity, importance of, 248
 - strategic IP management, in, 152–153
 - trademarks, 251–252
 - trade secrets, 250
- Posey, Darrell, 52
- Precautionary principle, 20
- Princeton University, 102
- Printers, 284
- Prior art, 178
- Privity, 93
- Prizes as alternative to IP rights, 58–59, 343
- Procurement practices, 153–156
 - criticism of IP, overcoming of, 155–156
 - freedom to operate, ensuring, 154–155
 - genetic sequences, 154–155
 - infringement claims, effect of, 155
 - licensing of assets, 154
 - overview, 153–154, 162
 - ownership of assets, 154
 - public domain, assets in, 154
 - risks, 154
 - what may be procured, 154
- Product development partnerships (PDPs), 110–111, 299
- Protection of innovation with IP rights
 - comparative law, 309
 - copyrights
 - high level of investment, 245
 - low level of investment, 245
 - notice, importance of, 244–245
 - overview, 244
 - decision-making process, 239
 - innovation triage (*See* Innovation triage)
 - IP assets, as, 242–244
 - nonprofit organizations, in, 239–240
 - overview, 239, 262
 - patents
 - applications, 247
 - costs, 247–248
 - invention disclosure requirements, 246–247
 - overview, 246
 - parallel protection, 247
 - provisional applications, 247
 - timing considerations, 248
 - trademarks
 - costs, 246
 - high level of investment, 245
 - low level of investment, 245–246
 - overview, 245
 - procedural requirements, 245
 - trade secrets
 - high level of investment, 244
 - overview, 244
 - self-help, 244
- Protection of IP rights. *See* Enforcement of IP rights
- Proudhon, Pierre-Joseph, 43
- PTO. *See* Patent and Trademark Office (US)
- Public agencies. *See* Governmental agencies
- Public disclosure
 - lack of, historical impact of, 28
 - promotion of, 39
- Public domain. *See also* “Accessible domain”
 - AIDS medicines and, 47
 - consumers, attitude of, 46–47
 - copyrights
 - dedication of, 250–251
 - entry of copyrighted material into, 72
 - dynamic relationship with IP, 46
 - false dichotomy with IP, 46, 47
 - innovation cycle, effect of, 46
 - IP contrasted, 45–46
 - joint ownership rights dedicated to, 89
 - keeping innovation out of as criticism of IP, 40
 - limitations of, 45–47
 - multiple public domains, concept of, 46
 - music and, 47
 - open access distinguished, 181–182
 - open innovation communities distinguished, 113
 - ownership of IP rights and, 267
 - trademarks, entry of, 75–76
 - trade secrets, entry of, 68–69
 - transfer of IP rights, inapplicability to, 86

Public Interest Intellectual Property Advisors (PIIPA)
 developing countries, delivery of IP services in, 57, 104, 122, 127, 204–205
 formation of, 42
 Ibis Reproductive Health and, 205
 International Alpaca Association and, 205
 Kenyan free trade coalition, assisting, 321
 Light Years IP, and, 205
 surveys by, 109

Public Library of Science, 182

Public performances
 comedy, copyrights and, 301
 dance, copyrights and, 301
 public speeches, copyrights and, 301
 strategic IP management, 299
 symphony orchestras
 copyrights and, 300–301
 importance of IP rights to, 300

theater
 copyrights and, 299–300
 importance of IP rights to, 300
 trademarks and, 300

Publishing licenses, 270

Pullman, David, 296

Pullman Group, 324

Purchasing. *See* Procurement practices

Qualcomm, 208, 222

Raghavan, Vijaya, 117

Rainforest Action Network, 335

Rajiv Gandhi School of Intellectual Property Law, 26

Rambus, 174–175

Ranbaxy, 117, 292

Rationale for IP, 37–40
 fruits of creativity, enjoyment of, 38
 incentive for creativity, 38
 industrial policy, implementation of, 40
 investment in innovation, facilitation of, 39–40
 moral rights, 38–39
 natural rights, 38–39
 overview, 36–37, 59
 public disclosure, promotion of, 39
 reward for creativity, 38
 transfer of innovation, facilitation of, 39

Real Options Theory, 219–220

Recording industry. *See* Music

Recording Industry Association of America, 47

Red Hat, 157

Reebok, 170

Regional innovation communities, 106–107

Relief from royalty model, valuation by, 217

Religious organizations
 copyrights and, 106
 innovation and, 105–106
 limitations of IP principles, 105
 morality, relevance of, 106
 symbols and, 105–106
 trademarks and, 106

Research in Motion (RIM) *See* Blackberry

Research organizations
 multinational research consortia (*See* Multinational research consortia)
 nonprofit organizations (*See* Nonprofit organizations)

Research tools, 376–378

Rivette, Kevin, 142

Roche, 208, 217, 222, 238, 319

Rome, IP in, 28

Royalties, 283

RoyaltyPharma, 189, 215, 221, 223, 324

Russia
 criminal offenses in, 314
 patents, volume of, 311
 piracy in, 313
 summary of IP law, 317

Rutan, Bert, 58

San Diego, University of California at, 113

Sandoz, 328

Santayana, George, 26

Saudi Arabia, role of negotiation in, 312

Scaled Composites, 58

Schawlow, Arthur, 176

Schering-Plough, 175, 329

Schumpeter, Joseph
 creative destruction theory, 11, 12, 19, 122
 dynamic innovation theory, 41

Science Commons Project, 276

Scotch Whisky Association, 318

Screening of innovations, 227–228

Securitization of IP rights
 advantages of, 323
 criticism of, 325
 examples of, 324
 growth in, 324
 innovation, impact on, 325
 market-driven nature of, 324–325
 obstacles to, 324
 overview, 322–323
 patent “trolls” compared, 325

Index

409

- Special Purpose Vehicles (SPVs), 323
 - table, 323
- Security interests, 270
- Sen, Amartya, 342
- Service contracts, 156–157
- Shakespeare, William, 19, 48, 229, 234, 300
- Shreeve, James, 109
- Shrinkwrap licenses, 271
- Shuster, Joe, 297
- Siegel, Jerry, 297
- Sierra Leone, summary of IP law, 320
- Sigma-Aldrich, 292
- Singapore, volume of patents in
- Singh, Malvinder, 117
- Small businesses
 - innovation and, 100–101
 - strategic IP management, 289–290
- Small groups and innovation, *See* Individuals and small groups and information
- Smallpox, 332
- Smith-Kline Beecham, 263
- Smithsonian Institution, 103
- Snap Trak, 208, 222
- Social value of IP assets, 223–224
- Social welfare and innovation, 342
- Software
 - confidentiality agreements and, 305–306
 - copyrights in, 293, 306
 - different types of IP involved, 79
 - licensing of IP rights, 307
 - access to innovation, 231
 - agreements, 85
 - end user license agreements (EULAs), 271, 307
 - internal asset evaluation, issues re, 195
 - open source software
 - innovation community model, 112
 - Linux (*See* Linux)
 - partnering practices, 157
 - patents in, 293, 306
 - strategic IP management, 293
 - trademarks in, 293, 306–307
 - trade secrets in, 293, 305
- Sony, 293
- Sophocles, 28
- Sources of innovation, 122–123
- South Africa
 - compulsory licenses in, 314
 - patents, standards for obtaining, 310, 311
 - summary of IP law, 320
- South Pacific, University of, 263
- Spain, Bolar provisions in, 314
- Special Purpose Vehicles (SPVs), 323
- Spiderman, 297
- Starbucks, 157
- State agencies. *See* Governmental agencies
- State Department, 332
- Statute of Monopolies, 30
- Stiglitz, Joseph, 41
- Stockholm Convention on Persistent Organic
 - Pollutants, 334
- Stolichnaya, 317
- Strategic alliances, 158
- Strategic IP management
 - “Aleppo Citadel” strategy, 170
 - “anti-invent around” strategy, 176
 - bargaining chip strategy, 170–171
 - “blanket” strategy, 173
 - branding, 179–180
 - “burning stick” strategy (*See* “Burning stick” strategy)
 - capital, consideration of, 144
 - communication of strategy, importance of, 164–165
 - comparative law, 308–309
 - competitive environment, studying, 144
 - benchmarking, 144
 - competitive intelligence and, 144
 - issues to assess, 144
 - conversion from patent to trademark, 175
 - copyright-specific strategies, 181
 - cost control model, 134–135
 - cost management (*See* Cost management)
 - defensive model, 134
 - development of plan, 144–145
 - access to IP assets of others, 145
 - copyrights and, 145
 - patents and, 145
 - protecting own IP assets, 145
 - “do-nothing” organizations, converting, 165
 - enforcement (*See* Enforcement of IP rights)
 - “fence” strategy, 173
 - “first one’s free” strategy, 172
 - “flood” strategy, 173
 - forest strategy, 169–170
 - forming strategy, 139
 - goals (*See* Goals of IP management)
 - growth stages, differences in
 - large businesses, 290
 - multinational corporations, 290
 - small businesses, 289–290
 - start-up companies, 289
 - table, 290
 - “homesteading” strategy, 172–173

- Strategic IP management (*cont.*)
- human resources, assessing, 141–142
 - globalization, impact of, 141
 - identifying creative personnel, 141
 - legal advice, 141
 - “hurdle” strategy, 174
 - implementation of plan, 145–146, 226–227
 - industries or sectors, differences in (*See also specific industry or sector*)
 - overview, 291
 - table, 291
 - integrated model, 135
 - “invent around” strategy, 175–176
 - inventory, consideration of, 144
 - IP practices, assessing, 143–144
 - IP resources, assessing, 142–143
 - existing assets, 142
 - goodwill, 142
 - valuation, 142–143
 - Level Five organizations, 135–136
 - Level Four organizations, 135
 - Level One organizations, 134
 - levels of, 131–132
 - Level Three organizations, 135
 - Level Two organizations, 134–135
 - Level Zero organizations, 132–134
 - minimalist strategy, 165–166
 - “move quickly and hold on” strategy, 180
 - “Mutual assured destruction” strategy, 171–172
 - non-policy parody, 361–364
 - non-strategy model, 132–134
 - confidentiality and, 133
 - consequences of, 132–133
 - copyrights, effect on, 133
 - patents, effect on, 133–134
 - reasons for, 132
 - trademarks, effect on, 134
 - options, 163, 164–165, 182–183
 - overview, 131, 136–139, 146, 307
 - partnering practices (*See Partnering practices*)
 - patent “jiu jitsu,” 175
 - patent-specific strategies, 172
 - patent traps, 174
 - personnel practices (*See Personnel practices*)
 - policing (*See Enforcement of IP rights*)
 - policy for IP management (*See Policy for IP management*)
 - portfolio management (*See Portfolio management*)
 - procurement practices (*See Procurement practices*)
 - profit center model, 135
 - screening of innovations, 227–228
 - simplicity of strategy, importance of, 164–165, 227
 - strategic reassessment (*See Strategic reassessment*)
 - “submarine” patents, 176–177
 - “suit of armor and shield” strategy, 167–168
 - supermonopoly, 174–175
 - supply chain management, 153–154
 - sword *versus* shield model, 171
 - technologies, differences in (*See also specific technology*)
 - overview, 301–302
 - table, 302
 - thicket strategy, 168–169
 - tight budget strategy, 166
 - “toll gate” strategy, 173–174
 - tools for, 147–148, 162
 - trademark clusters, 180–181
 - trademark-specific strategies, 179–181
 - trade secrets
 - IP practices as, 143
 - trade secret-specific strategies, 178–179
 - trade secrets *versus* patents, 179
 - treble damages, avoiding, 177
 - uncited prior art, 178
 - unnamed co-inventors, 178
 - visionary model, 135–136
 - copyrights, effect on, 135–136
 - patents, effect on, 136
 - “wall” strategy, 174
- Strategic reassessment, 161–162
- financial valuation, 161
 - noneconomic valuation, 161
 - simplicity of plan, importance of, 161–162
- Sublicenses, 271, 280
- “Submarine” patents, 176–177
- “Suit of armor and shield” strategy, 167–168
- Sullivan, Patrick, 23, 126
- Sunk cost-based valuation. *See* Cost-based valuation
- Superman, 79, 297
- Supermonopoly, 174–175
- Supply chain management, 153–154
- Swanson, Robert, 117
- Swift, Jonathan, 208
- Sword *versus* shield model, 171

Index

411

- Symbol Technologies, 177
- Symphony orchestras
 - copyrights and, 300–301
 - importance of IP rights to, 300
- Taiwan
 - compulsory licenses in, 314
 - summary of IP law, 319
- Tamiflu, 331
- Tangible property
 - copyrights separate from, 275
 - licensing of IP rights, effect of transfer on, 271–272
 - ownership of IP rights distinguished from ownership of tangible property, 268
 - transfer of IP rights, tangible property analogy, 84
- Taxol, 329
- Teams. *See* Innovation teams
- Technical manuals, 79
- Technology licenses, 270
- Telecommunications
 - copyrights in, 293
 - patents in, 293
 - strategic IP management, 293
 - trademarks in, 293
 - trade secrets in, 293
- Termination clauses, 280–281
- Terrorism. *See* Homeland security technology
- Teva, 329
- Texas Instruments, 293
- Thailand, compulsory licenses in, 314
- Theater
 - copyrights and, 299–300
 - importance of IP rights to, 300
 - trademarks and, 300
- Thicket strategy, 168–169
- Third-party IP rights, 237
- Thompson, Tommy, 329
- Thoreau, Henry David, 227
- Tight budget strategy, 166
- Time Magazine, 113
- “Toll gate” strategy, 173–174
- Townes, Charles, 14, 176
- Toyota, 174, 227
- Trademarks, 73–76
 - abandonment, 251–252
 - balancing access and exclusion in, 45, 52
 - biological materials, in, 292–293, 304
 - comparative law re standards for obtaining, 311–312
 - consumer products and services, in, 294
 - conversion to different type of IP, 79–81
 - developing countries and, 108
 - dilution, 75
 - distinctiveness, concept of, 74–75
 - duration, 75
 - electromechanical equipment, in, 305
 - electronics, in, 293
 - enforcement of, 75, 260
 - entertainment industry, in, 297
 - environmental technology, in, 335
 - EU, community trademarks in, 245, 316
 - external environment evaluation (*See* External environment evaluation)
 - fair use of, 235
 - infringement, damages, 222
 - interactions with other types of IP, 78–79
 - internal asset evaluation re (*See* Internal asset evaluation)
 - licenses, 270–271
 - life sciences, in, 292–293
 - loss of rights, 75
 - Madrid Protocol, under, 245, 316
 - maintenance, 251
 - music, in, 297
 - non-strategy model of IP management, effect of, 134
 - obtaining, 73–74
 - overview, 73, 83
 - ownership of, 267
 - pharmaceuticals, in, 292–293
 - portfolio management, 251–252
 - protection of innovation
 - costs, 246
 - high level of investment, 245
 - low level of investment, 245–246
 - procedural requirements, 245
 - public domain, entry into, 75–76
 - religious organizations and, 106
 - renewal, 251
 - software, in, 293, 306–307
 - strategic IP management, trademark-specific strategies, 179–181
 - sunk cost-based valuation, 212
 - table, 74
 - telecommunications, in, 293
 - theater and, 300
 - trademark clusters, 180–181
 - transfer of IP rights, 276

- Trademarks (*cont.*)
 TRIPS Agreement, protection under, 245
 universities and, 298, 299
- Trade secrets, 67–69
 balancing access and exclusion in, 45, 52
 biological materials, in, 79, 292, 302
 confidentiality agreements, breach of, 259
 consumer products and services, in, 294–295
 conversion to different type of IP, 79–81
 copyrights, relationship with, 69
 definition of, 67
 electronics, in, 293
 enforcement of, 68, 257–259
 entertainment industry, in, 295
 environmental technology, in, 335
 external environment evaluation (*See*
 External environment evaluation)
 fair use of, 236
 genetic sequences, in, 302–303
 homeland security technology, in, 332
 human genome and, 69
 infringement, damages, 222
 interactions with other types of IP, 78–79
 internal asset evaluation re (*See* Internal asset
 evaluation)
 life sciences, in, 292
 loss of status, 68–69
 nonprofit organizations and, 297
 overview, 67, 83
 ownership of, 267
 patents, relationship with, 69
 pharmaceuticals, in, 292
 portfolio management, 250
 protection of, 67
 protection of innovation
 high level of investment, 244
 low protection, 243
 self-help, 244
 public domain, entry into, 68–69
 secrecy, concept of, 68
 “self-help,” 67
 software, in, 293, 305
 strategic IP management
 IP practices as, 143
 trade secret-specific strategies, 178–179
 trade secrets *versus* patents, 179
 sunk cost-based valuation, 212
 table, 67
 telecommunications, in, 293
 theft of, 152, 257–259
 transfer of IP rights, 274
 TRIPS Agreement
 fair use under, 236
 protection under, 244
 universities and, 297
 violations, 67–68
- Traditional knowledge, 52, 77–78, 318, 336, 337
- Traffic Devices, 175
- Transfer of IP rights
 ABCD model (*See* ABCD model of transfer of
 IP rights)
 acquisition of IP rights (*See* Acquisition of IP
 rights)
 assignment (*See* Assignment of IP rights)
 basic principles, 264
 collaborators, 89–90
 complexity of, 84
 consideration, 264–265
 contracts, 87
 copyrights, 275–276
 consulting agreements, 275
 “copyleft” licenses, 276
 open access licenses, 275–276
 overview, 275
 tangible property, separation from, 275
- full transfer, 87
 individual transfer of IP rights, 86
 infringement (*See* Infringement)
 joint ownership, 89–90
 legal language, 265
 licensing (*See* Licensing of IP rights)
 management, importance of, 84
 mutual assent, 265
 negotiating considerations
 comparative law re, 312
 consensus building, 285
 flexibility, 285
 goals of, 285
 human factor, 284–285
 noneconomic terms, 285
 overview, 86–87
 research, 285
 strategic planning, 285
- overview, 84, 95–96, 263, 285–286
 ownership of IP rights (*See* Ownership of IP
 rights)
 partial transfer, 87
 patents, 274–275
 property that may be transferred, 85–86
 public domain, inapplicability of, 86
 rights that may be transferred, 85–86
 scope of license, determining, 86
 specialists, role of, 284
 tangible property analogy, 84

Index

413

- trademarks, 276
- trade secrets, 274
- types of transfers, 268
- writing, importance of, 265
- Treble damages, avoiding, 177
- Tree metaphor, *See* Innovation tree metaphor
- Trends in IP system, 56–59
 - “accessible domain,” enlargement of, 57
 - continued importance of IP, 59
 - “creative construction,” 57–58
 - file reproduction technology, 56
 - future scenarios, 338
 - business, 339
 - governments, 339
 - political groups, 340
 - technologies, 340
 - grants and prizes as alternative to IP rights, 58–59
 - law, limitations of, 58
 - new groups, involvement of, 56
 - pharmaceuticals, in, 56
 - possible outcomes
 - expansion of IP protection, 57
 - rollback of IP protection, 57
 - social goals, promotion of, 57
 - status quo, preservation of, 56–57
 - predictions, 58
- Triage
 - enforcement triage (*See* Enforcement triage)
 - innovation triage (*See* Innovation triage)
- TRIPS Agreement
 - adoption of, 25
 - balancing access and exclusion, 52
 - biological materials under, 303
 - compulsory licenses under, 314, 330
 - convergence of national laws resulting from, 308, 309
 - copyright protection under, 244
 - definition of IP, 23
 - developing countries, lack of full implementation in, 309
 - drug patents under, 330
 - Eurocentric nature of, 53
 - excerpts, 346–360
 - geographical indications under, 76
 - historical background, 33
 - India, laws adopted in compliance with, 117
 - integrated circuits under, 305
 - involvement of new groups under, 56
 - laws adopted in compliance with, 43, 65–66
 - patents
 - consistency re, 310
 - fair use of, 236
 - protection of, 246
 - plant patents under, 71
 - protection of IP rights generally, 244
 - public order or morality, inventions contrary to, 303
 - tensions under, 53
 - trademark protection under, 245
 - trade secrets
 - fair use of, 236
 - protection of, 244
 - widespread adoption of, 53
- Tucker Act, 332
- Turner, Ted, 38
- 25% rule in valuation, 221
- Tylenol, 124
- Types of IP
 - biological materials, 77
 - conversion to different type, 79–81
 - copyrights (*See* Copyrights)
 - databases, 77
 - domain names, 76
 - employee rights, 77
 - geographical indications, 76–77
 - interactions between, 78–79
 - overview, 76, 82–83
 - patents (*See* Patents)
 - trademarks (*See* Trademarks)
 - trade secrets (*See* Trade secrets)
 - traditional knowledge, 77–78
- Uniform Domain Name Dispute Resolution Policy, 313
- Union Oil Company of California, 174
- United International Bureau for the Protection of Intellectual Property, 22, 32
- United Nations, use of copyrights by, 202
- United States
 - Bolar provisions in, 314
 - Commerce Department, 332
 - Constitution
 - Eleventh Amendment, 332
 - IP under, 24–25
 - environmental regulation in, 333
 - Federal Trade Commission, 174, 284, 329
 - Homeland Security Act of, 2002, 331
 - patents
 - standards for obtaining, 310
 - volume of, 311
 - summary of IP law, 315
 - Trade Representative, 313
- Universal Declaration of Human Rights, 55, 337

Universities

- academic freedom in, 298
- assignment of IP rights and, 269–270
- Bayh-Dole Act, impact of, 34, 103, 297
- copyrights and, 299
- foreign universities, 298–299
- innovation and, 102–103
- internal assets valuation in, 189
- patents and, 297–298
- publication by, 297, 298
- strategic IP management, 297
- trademarks and, 298, 299
- trade secrets and, 297
- valuation of IP assets, 222–223
- UPOV. *See* International Union for the Protection of New Varieties of Plants
- U.S. Pharmacopeia, 292
- Utility patents, 70

Valuation of IP assets

- auctioning of assets, 219
- Black-Scholes option pricing formula, 219–220
- cash value model (*See* Income-based valuation)
- commercial ventures, in, 208
- comparables, by (*See* Market-based valuation)
- cost-based valuation (*See* Cost-based valuation)
- differing approaches, 209–210
- discounted cash flow, calculation of, 214, 216
- driving force of IP system, as measure of, 224
- established royalty rates, use of, 220
- fair market valuation (*See* Market-based valuation)
- 5% rule, 220–221
- Georgia-Pacific factors, 218–219
- governmental agencies, 222–223
- hybrid methods, 218–220
- hypothetical royalty negotiations, 218–219
- importance of, 207–210
- income-based valuation (*See* Income-based valuation)
- licensing situations, 222
- methods of, 210
- monetizing of assets, 223
- net present value, calculation of, 214, 216
- nonprofit organizations, in, 208–209
- overview, 185, 207–208, 224–225
- ownership of asset, relevance of, 210
- patent counting, 223

- purposes of, 210
- Real Options Theory, 219–220
- relief from royalty model, 217
- replacement cost-based valuation, 213–214
- rules of thumb, 220–221
- social value, 223–224
- statistics re, 208
- strategic IP management, as part of, 142–143
- sunk cost-based valuation (*See* Cost-based valuation)
- table, 211
- threshold questions, 210
- 25% rule, 221
- type of IP, relevance of, 210
- universities, 222–223
- Venetian Patent Decree of 1474, 29–31
 - enactment of, 37
 - enforcement under, 253
 - influence of, 31
 - infringement under, 29
 - mechanical devices, applicability to, 305
 - overview, 29
 - patents issued under, 29
 - provisions of, 30–31
 - text of, 31
- Venezuela, summary of IP law, 320
- Venter, Craig, 14, 16, 110, 118, 303
- Viagra, 319, 328
- Vioxx, 328
- Volkswagen, 152, 259
- Voltaire, 208, 333
- “Wall” strategy, 174
- Wal-Mart, 294
- Walt Disney Company, 79, 100, 117, 295
- Warranties, 281–283
- Watson, James, 303
- Watt, James, 14
- White, Tony, 118
- Wikipedia
 - “copyleft” licenses, 42, 112
 - copyrights and, 229
 - editing of, 49
 - GNU Free Documentation License, 276
 - internal IP assets, evaluation of, 188–189
 - open access and, 43, 140, 182
 - public domain and, 45
- Wilson, E.O., 17
- Woods, Tiger, 188
- World Health Organization (WHO)
 - copyrights, use of, 202
 - disease, initiatives to fight, 111

Cambridge University Press

978-0-521-70169-3 - Driving Innovation: Intellectual Property Strategies for a Dynamic World

Michael A. Gollin

Index

[More information](#)**Index****415**

- pharmaceuticals and developing countries,
 - report on, 55–56
- World Intellectual Property Organization (WIPO)
 - Arbitration and Mediation Center, 313
 - copyrights, use of, 202–203
 - Copyright Treaty, 296
 - definition of IP, 22–23
 - domain names, arbitration system re, 112
 - historical background, 32
 - involvement of new groups, 56
 - patents, statistics on, 311
 - piracy, report on, 313
 - rational for IP rights, 36
 - record searches, 199
 - traditional knowledge, protection of, 78
 - Uniform Domain Name Dispute Resolution Policy, 313
- World Trade Organization (WTO)
 - Doha Declaration, 314
 - historical background, 33
 - TRIPS Agreement (*See* TRIPS Agreement)
- Wozniak, Steven, 151, 152
- W.R. Grace, 234
- Wright brothers, 14
- Xerox, 75
- Yale University, 324
- YouTube, 113, 136
- Zostrix, 234